Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Schering-Plough In Cancer Drug Deal
June 4, 2007
| A version of this story appeared in
Volume 85, Issue 23
Schering-Plough has licensed the prostate cancer treatment Asentar from the South San Francisco-based biotech firm Novacea. Novacea is in the midst of a Phase III trial of Asentar, a high-dose oral form of the hormone calcitriol that works through the vitamin D receptor. Under the deal, Schering-Plough will pay Novacea $60 million up front, make a $25 million licensing payment, and buy $12 million of Novacea stock. Schering-Plough could pay up to $380 million more in milestone payments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter